Hepatic very low-density lipoprotein assembly pathway

The hepatic VLDL assembly pathway consists of molecular and cellular events in hepatocytes that coordinate the synthesis, lipidation, and secretion of very low-density lipoprotein particles. The process begins with the translation and translocation of Apolipoprotein B-100 in the rough endoplasmic reticulum, lipidation by microsomal triglyceride transfer protein, formation of nascent VLDL, and subsequent maturation and secretion into the bloodstream. VLDL particles transport endogenously synthesized triglycerides and cholesterol esters from the liver to peripheral tissues. Dysregulation of this pathway is implicated in metabolic diseases, including fatty liver, hypertriglyceridemia, and atherosclerosis.

Other names

VLDL biogenesis pathwayHepatic VLDL secretion pathway

For drugs targeting pathway components:\n- Inhibition of microsomal triglyceride transfer protein reduces VLDL assembly\n- Antisense reduction of ApoB-100 impairs VLDL formation